Sclerostin as a new target of diabetes-induced osteoporosis
Sclerostin, a protein synthesized by bone cells, is a product of the SOST gene. Sclerostin is a potent soluble inhibitor of the WNT signaling pathway, and is known to inhibit bone formation by inhibiting osteocyte differentiation and function. Currently, sclerostin has been the subject of numerous a...
Saved in:
| Main Authors: | Yanhua Li, Yaheng Luo, Debin Huang, Lele Peng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1491066/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus
by: Cyril Traechslin, et al.
Published: (2025-06-01) -
Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
by: Shi-Hsun Chiu, et al.
Published: (2024-12-01) -
Diabetes mellitus: A risk factor for the development of osteoporosis
by: Vuksanović Miljanka, et al.
Published: (2008-01-01) -
Progress of studies on sclerostin’s role in vascular calcification of chronic kidney disease
by: PENG Qiong-yao, et al.
Published: (2019-01-01) -
The serum levels of FGF23, sclerostin, osteoprotegerin do not explain the inverse relationship between coronary calcifications and bone mineral density evaluated using computed tomography
by: Laurence Ferrières, et al.
Published: (2025-06-01)